Valuing innovative endoscopic techniques: Hemostatic powder for the treatment of gastrointestinal tumor bleeding

Eric D. Shah,Ryan Law
DOI: https://doi.org/10.1016/j.gie.2023.12.036
IF: 10.396
2024-01-06
Gastrointestinal Endoscopy
Abstract:BACKGROUND AND AIMS Access to new endoscopic treatment modalities often depends on price. To resolve this gap and therefore help to ensure that care delivery can occur on a clinical basis, we aimed to establish the value to insurers of novel hemostatic powder to treat gastrointestinal tumor bleeding. METHODS A decision-analytic model developed to assess the impact of endoscopic intervention on the risk of 30-day readmission for gastrointestinal bleeding from an insurer perspective, was adapted to assess gastrointestinal tumor bleeding with hemostatic powder or standard endoscopic therapy. Costs were derived from Medicare populations. Outcomes were derived from a recent multicenter randomized clinical trial. RESULTS 1,613 to treat upper gastrointestinal tumor bleeding and 1,014 to treat lower gastrointestinal tumor bleeding based on risk reduction in 30-day hospital re-admission for re-bleeding. These valuations should represent medical device and incremental facility costs in addition to incremental physician and staff time. CONCLUSIONS Coverage for novel endoscopic hemostatic powder therapy appears cost-saving to insurers.
gastroenterology & hepatology
What problem does this paper attempt to address?